View More View Less
  • 1 Országos Reumatológiai és Fizioterápiás Intézet, Budapest
  • | 2 Jahn Ferenc Dél-pesti Kórház, Budapest
  • | 3 Budai Irgalmasrendi Kórház, Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest
  • | 4 Magyar Általános Orvosok Tudományos Egyesülete, Budapest
  • | 5 Országos Sportegészségügyi Intézet, Budapest
  • | 6 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen
Open access

Absztrakt:

A tanulmány szerzői a napi gyakorlatban a leggyakrabban fellépő mozgásszervi panaszok hátterében álló regionális fájdalmi szindrómák leggyakoribb kezelési módjával, a per os és transdermalisan alkalmazott nem szteroid gyulladáscsökkentőkkel végzett fájdalomcsillapításról rendelkezésre álló bizonyítékokat gyűjtötték össze. Azon szakterületeken működők számára, akik leggyakrabban találkoznak az átmeneti és fájdalmas epizódokkal (háziorvosok, reumatológusok, ortopédek, foglalkozás-egészségügyi és sportorvosok), külön meghatározták a foglalkozási vagy sporttevékenységük (a mozgásszervek ismétlődő vagy nagy energiájú igénybevétele) miatt kockázatnak kitettek körét és ismertetik fájdalmaik patológiai magyarázatát. A fájdalomcsillapítás eszközei között részletezik a nem szteroid gyulladáscsökkentők hatásának módját és farmakológiai sajátosságait. Kiemelik a gyógyszeres kezelés kockázatait és az emiatt veszélyeztettek speciális csoportjait (gyermekkorúak és idősek). Az általános fájdalomcsillapítási alapelvek és stratégiák ismertetésén túlmenően a hazai és nemzetközi irányelvekből a tanulmány tárgyára vonatkozó ajánlásokat adják közre. Orv Hetil. 2017; 158(Suppl. 3): 3–30.

  • 1

    WHO Handbook for guideline development, March 2014.

  • 2

    Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924–926.

  • 3

    Guyatt GH, Oxman AD, Aki EA, et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64: 383–394.

  • 4

    National Collaborating Centre for Methods and Tools (2011). Critically appraising practice guidelines: The AGREE II instrument. McMaster University, Hamilton, ON. (Updated 12 September, 2017). Retrieved from: http://www.nccmt.ca/knowledge-repositories/search/100

  • 5

    Generaal E, Vogelzangs N, Macfarlane GJ, et al. Biological stress systems, adverse life events and the onset of chronic multisite musculoskeletal pain: a 6-year cohort study. Ann Rheum Dis. 2016; 75: 847–854.

  • 6

    Voscopoulos C, Lema M. When does acute pain become chronic? Br J Anaesth. 2010; 105(Suppl 1): i69–i85.

  • 7

    Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest. 2010; 120: 3779–3787.

  • 8

    Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. Neuron 2007; 55: 377–391.

  • 9

    Amaya F, Izumi Y, Matsuda M, et al. Tissue injury and related mediators of pain exacerbation. Curr Neuropharmacol. 2013; 11: 592–597.

  • 10

    Cohen SP, Mao J. Neuropathic pain: mechanisms and their clinical implications. BMJ 2014; 348: 1756–1768.

  • 11

    Riccioti E, Fitzgerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011; 31: 986–1000.

  • 12

    Simmons DL, Botting RM, Hla T. Cyclooxigenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004; 56: 367–436.

  • 13

    Poór Gy. (ed.) Rheumatology. [Reumatológia.] Medicina Könyvkiadó, Budapest, 2008. [Hungarian]

  • 14

    Mester Á. Opportunities of magnetic resonance imaging in the diagnostics of musculoskeletal diseases. [A mágneses rezonanciás vizsgálatok lehetőségei a musculoskeletalis diagnosztikában.] LAM 2004; 14: 771–779. [Hungarian]

  • 15

    Ungváry Gy. Health care for occupational diseases. [Munkaegészségtan.] Medicina Könyvkiadó, Budapest 2004; pp. 686–694. [Hungarian]

  • 16

    Kellgren JH, Lawrence JS. Rheumatism in miners. Part II: X-ray study. Br J Ind Med. 1952; 9: 197–207.

  • 17

    Björkstén MG, Boquist B, Talbäck M, et al. Neck and shoulder ailments in a group of female industrial workers with monotonous work. Ann Occup Hyg. 1996; 40: 661–673.

  • 18

    Caplan PS, Freedman LM, Conelly TP. Degenerative joint disease of the lumbar spine in coal miners – a clinical and X-ray study. Arthritis Rheum. 1996; 9: 693–702.

  • 19

    Zejda JE, Gaździk TS, Czekaj I. Low back pain syndrome in coal miners: preliminary results of an epidemiological study. Med Pr. 1998; 49: 353–361.

  • 20

    Latza U, Karmaus W, Stürmer T, et al. Cohort study of occupational risk factors of low back pain in construction workers. Occup Environ Med. 2000; 57: 28–34.

  • 21

    Snook SH. Work-related low back pain: secondary intervention. J Electromyogr Kinesiol. 2004; 14: 153–160.

  • 22

    Magnavita N, Elovaino M, De Nardis I, et al. Environmental discomfort and musculoskeletal disorders. Occup Med. (Lond.) 2011; 61: 196–201.

  • 23

    Pienimäki T. Cold exposure and musculoskeletal disorders and diseases. A review. Int J Circumpolar Health 2002; 61: 173–182.

  • 24

    Dovrat E, Katz-Leurer M. Cold exposure and low back pain in store workers in Israel. Am J Int Med. 2007; 50: 626–631.

  • 25

    Staal JB, Hlobil H, van Tulder MW, et al. Occupational health guidelines for the management of low back pain: an international comparison. Occup Environ Med. 2003; 60: 618–626.

  • 26

    Vereckei E, Susanszky E, Kopp M, et al. Psychosocial, educational, and somatic factors in chronic nonspecific low back pain. Rheumatol Int. 2013; 33: 587–592.

  • 27

    Madden CC, Putukian M, Young CC, et al. (eds.) Sports pharmacology of pain and inflammation control in athletes. In: Netter’s sportsmedicine. Saunders, Elsevier, Philadelphia, 2010; pp. 47–51, 171–183.

  • 28

    Feucht CL, Patel DR. Analgesics and anti-inflammatory medications in sports: use and abuse. Pediatr Clin North Am. 2010; 57: 751–774.

  • 29

    Lippi G, Franchini M, Guidi GC. Non steroidal anti-inflammatory drugs (NSAIDs) in athletes. Br J Sports Med. 2006; 40: 661–663.

  • 30

    The World Anti-Doping Code. The 2010 Prohibited List. International Standard. WADA website

  • 31

    Rheumatology and Physiotherapy Board. Analgetic and antiinflammatory drug treatment of rheumatologic diseases. Guideline of the Ministry of Health Care (invalid). [Reumatológiai és Fizioterápiás Szakmai Kollégium. A gyógyszeres fájdalomcsillapításról és gyulladásgátlásról a reumatológiai betegségekben. Az Egészségügyi Minisztérium szakmai protokollja (hatályon kívül helyezve).] Egészségügyi Közlöny 2005; 21: 3532–3541. [Hungarian]

  • 32

    Assessment and management of chronic pain. Health Care Guideline Institute for Clinical Systems Improvement, 2013. http://www.icsi.org

  • 33

    Myers J, Wielage RC, Han B, et al. The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis. BMC Musculoskelet Disord. 2014, 15: 76–100.

  • 34

    Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician 2008; 11(2 Suppl): S133–S153.

  • 35

    Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc. 2010; 85(3 Suppl): S3–S14.

  • 36

    Derry S, Conaghan P, Da Silva JA, et al. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database of Systematic Reviews 2016; 4: CD007400.

  • 37

    Rannou F, Pelletier JP, Martel-Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016; 45(4 Suppl): S18–S21.

  • 38

    Szamosi Sz. Application of topical application of non-steroidal antiinflammatory drugs for pain relief in rheumatology. [A topikus nem szteroid gyulladásgátló helye a reumatológiai fájdalomcsillapításban.] Magy Reumatol. 2017; 58: 20–24. [Hungarian]

  • 39

    Hochberg MC, Altman RC, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012; 64: 465–474.

  • 40

    Järvinen TA. Muscle injuries: optimising recovery. Best Pract Res Clin Rheumatol. 2007; 21: 317–331.

  • 41

    Haroutiunian S, Drennan DA, Lipman AG. Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010; 11: 535–549.

  • 42

    Mazières B, Rouanet S, Guillon Y, et al. Topical ketoprofen patch in the treatment of tendinitis: a randomized, double-blind, placebo controlled study. J Rheumatol. 2005; 32: 1563–1670.

  • 43

    Mazières B, Rouanet S, Velicy J, et al. Topical ketoprofen patch (100 mg) for the treatment of ankle sprain: a randomized, double-blind, placebo-controlled study. Am J Sports Med. 2005; 33: 515–523.

  • 44

    Moore RA, Tramer MR, Carroll D. Quantitative systematic review of topically applied NSAIDs. BMJ 1998; 316: 333–338.

  • 45

    Mehallo CJ, Drezner JA, Bytomski JR. Practical management: NSAIDs use in athletic injuries. Clin J Sport Med. 2006; 16: 170–174.

  • 46

    Dahners LE, Gilbert JA, Lester GE, et al. The effect of a non-steroidal antiinflammatory drug on the healing of ligaments. Am J Sports Med. 1988; 16: 641–646.

  • 47

    Elder CL, Dahners LE, Weinhold PD. A Cox-2 inhibitor impairs ligament healing in the rat. Am J Sports Med. 2001; 29: 801–805.

  • 48

    Moorman CT, Kukreti U, Fenton DC. The early effect of ibuprofen on the mechanical properties of healing medial collateral ligament. Am J Sports Med. 1999; 27: 738–741.

  • 49

    Andres BM, Murrell GA. Treatment of tendinopathy: what works, what does not, and what is on the horizon. Clin Orthop Relat Res. 2008; 466: 1539–1554.

  • 50

    Marsolais D, Coté CH, Frenetta J. NSAIDs reduce neutrophil and macrophage accumulation but does not improve tendon regeneration. Lab Invest. 2003; 83: 991–999.

  • 51

    Petri M, Hufman SL, Waser G, et al. Celecoxib effectively treats patients with acute shoulder tendonitis/bursitis. J Rheumatol. 2004; 31: 258–260.

  • 52

    Lanier AB. Use of nonsteroidal anti-inflammatory drugs following exercise induced muscle injury. Sports Med. 2003; 33: 177–186.

  • 53

    Osterwalder A, Reiner V, Reiner G, et al. Tissue absorption and distribution of ketoprofen after patch application in subject undergoing knee arthroscopy or endoscopic carpal ligament release. Arzneimittelforschung 2002; 52: 822–827.

  • 54

    Rolf C, Movin T, Engstrom B, et al. An open, randomized study of ketoprofen in patients surgery for Achilles or patellar tendinopathy. J Rheumatol. 1997; 24: 1595–1598.

  • 55

    Rolf C, Engström B, Beauchard C, et al. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology 1999; 38: 564–567.

  • 56

    Larson CM, Almekinders LC, Karas SG, et al. Evaluating and managing muscle contusions and myositis ossificans. Phys Sports Med. 2002; 30: 41–46.

  • 57

    Kumaresan C. S+ ibuprofen (dexibuprofen): the superior non steroidal anti-inflammatory agents for development of pharmaceuticals. Int J Curr Pharm Res. 2010; 2(3): 1–3.

  • 58

    Warner TD, Giuliano F, Vojnovic I. et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity. A full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563–7568.

  • 59

    Szekanecz Z. Questions and answers on the non-steroidal antinflammatory drugs and cylo-oxygenase-2 inhibitors. [Kérdések és válaszok a nem szteroid gyulladáscsökkentőkről és a COX-2-gátlókról.] Háziorvosi Továbbképző Szemle 2003; 8: 590–594. [Hungarian]

  • 60

    Gachályi B. Introduction into clinical pharmacology. [Bevezetés a klinikai farmakológiába.] Springer Hungarica, Budapest, 1992; pp. 25–73. [Hungarian]

  • 61

    FDA Draft guidance on menthol, methyl salicylate. Revised 2016. https://www.fda.gov/downloads/Drugs/Guidance_ComplianceRegulatoryInformation/Guidances/UCM406333.pdf

  • 62

    McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22: 363–388.

  • 63

    Martin D, Valdez J, Boren J, et al. Dermal absorption of camphor, menthol, and methyl salicylate in humans. J Clin Pharmacol. 2004; 44: 1151–1157.

  • 64

    Higashi Y, Kiuchi T, Furuta K. Efficacy and safety profile of a topical methyl salicylate and menthol patch in adult patients with mild to moderate muscle strain: A randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Clin Ther. 2010; 32: 34–43.

  • 65

    Yano T, Nakagawa A, Tsuji M, et al. Skin permeability of various non-steroidal anti-inflammatory drugs in man. Life Sci. 1986; 39: 1043–1050.

  • 66

    Sekiya I, Morito T, Hara K, et al. Ketoprofen absorption by muscle and tendon after topical or oral administration in patients undergoing anterior cruciate ligament reconstruction. AAPS Pharm Sci Tech. 2010; 11: 154–158.

  • 67

    Papp R, Bálint G. Investigation of effectivity, tolerability and patient compliance of KEPLAT® 20 mg drug patch in patients with acute musculoskeletal complaints. [KEPLAT® 20 mg gyógyszeres tapasz hatásosságának, tolerálhatóságának és a beteg együttműködésének vizsgálata akut mozgásszervi betegeknél.] Magy Reumatol. 2013; 54: 183–187. [Hungarian]

  • 68

    Fine PG. Treatment guidelines for the pharmacological management of pain in older persons. Pain Med. 2012; 13: S57–S66.

  • 69

    Park KE, Qin Y, Bavry AA. Nonsteroidal anti-inflammatory drugs and their effects in the elderly. Aging Health 2012; 8: 167–177.

  • 70

    Taylor R Jr, Lemtouni S, Weiss K, et al. Pain management in the elderly: an FDA safe use initiative expert panel’s view on preventable harm associated with NSAID therapy. Curr Gerontol Geriatr Res. 2012; 2012: Article ID 196159.

  • 71

    Recommendations for FDA interventions to decrease the occurrence of acetaminophen hepatotoxicity 2008. http://www.fda.gov/Guidances/UCM164098

  • 72

    Gazarian M, Graudins LV. Safe use of non-steroidal anti-inflammatory drugs in infants and children. Med Today 2006; 7: 71–73.

  • 73

    Information on paediatric rheumatic disease. Drug therapy. [Tájékoztatás a gyermekkori reumás megbetegedésekről. Gyógyszeres kezelés.] Available from: https://www.printo.it/pediatric-rheumatology/HU/info/15/ [Hungarian]

  • 74

    Lewis SR, Nicholson A, Cardwell ME, et al. Nonsteroidal anti-inflammatory drugs and perioperative bleeding in paediatric tonsillectomy. Cochrane Database Syst Rev. 2013; 7: CD003591.

  • 75

    Levy DM, Imundo LF. Nonsteroidal anti-inflammatory drugs: a survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data. Pediatr Rheumatol Online J. 2010; 8: 7.

  • 76

    Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal antiinflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000; 160: 2093–2099.

  • 77

    Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006; 114: 1028–1235.

  • 78

    Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs. An update for clinicians: a scientific statement from the American Heart Association. Circulation 2006; 115: 1634–1642.

  • 79

    Lanas A, Garcia-Tell G, Armada B, et al. Prescription pattern and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med. 2011; 9: 38.

  • 80

    Valkhoff VE, van Soest EM, Sturkenboom MC, et al. Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Aliment Pharmacol Ther. 2010; 31: 1218–1228.

  • 81

    Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005; 129: 1171–1118.

  • 82

    Bhala N, Emberson J, Merhi A, et al., Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382: 769–779.

  • 83

    Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113: 2906–2913.

  • 84

    Schjerning OA, Fosbol EL, Lindharsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011; 123: 2226–2235.

  • 85

    Olsen AM, Fosbol EL, Lindhardsen J, et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study. Circulation 2012; 126: 1955–1963.

  • 86

    Perry LA, Mosler C, Atkins A, et al. Cardiovascular risk associated with NSAIDs and COX-2 inhibitors. US Pharm. 2014; 39: 35–38.

  • 87

    European Medicines Agency. Updated advice on use of high-dose ibuprofen. EMA 325007/2015. 22 May 2015.

  • 88

    Schjerning Olsen AM, Fosbøl EL, Gislason GH. The impact of NSAID treatment on cardiovascular risk – on sight of Danish observational data. Basic Clin Pharmacol Toxicol. 2014; 115: 179–184.

  • 89

    Becker MC, Wang TH, Wisniewski L, et al. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009; 157: 606–612.

  • 90

    Bello AE, Holt JR. Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications. Drug Saf. 2014; 37: 897–902.

  • 91

    Horváth VJ, Tabák GÁ, Szabó G, et al. Cardiovascular side effects of non-steroidal anti-inflammatory drugs in the light of recent recommendations. Diclofenac is not more dangerous. [A nem szteroid gyulladásgátló készítmények cardiovascularis mellékhatásai a legújabb ajánlások fényében. Nem veszélyesebb a diclofenac.] Orv Hetil. 2015; 156: 516–520. [Hungarian]

  • 92

    Haag MD, Bos MJ, Hofman A, et al. Cyclooxygenase selectivity of nonsteroidal anti inflammatory drugs and risk of stroke. Arch Intern Med. 2008; 168: 1219–1224.

  • 93

    Barthelemy O, Limbourg T, Collet JP, et al. Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. Int J Cardiol. 2013; 163: 266–271.

  • 94

    Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363: 1751–1756.

  • 95

    Feenstra J, Heerdink ER, Grobbee DE, et al. Association of nonsteroidal anti inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med. 2002; 162: 265–270.

  • 96

    Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000; 160: 777–784.

  • 97

    Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009; 169: 141–149.

  • 98

    Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994; 121: 289–300.

  • 99

    Krum H, Swergold G, Curtis SP, et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009; 27: 886–893.

  • 100

    Chrischilles EA, Wallace RB. Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population. J Gerontol. 1993; 48: M91–M96.

  • 101

    Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005; 165: 161–168.

  • 102

    Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002; 90: 959–963.

  • 103

    Chao TF, Liu CJ, Chen SJ, et al. The association between the use of non-steroidal anti-inflammatory drugs and atrial fibrillation: a nationwide case-control study. Int J Cardiol. 2013; 168: 312–316.

  • 104

    Liu G, Yan YP, Zheng XX, et al. Meta-analysis of nonsteroidal anti-inflammatory drug use and risk of atrial fibrillation. Am J Cardiol. 2014; 114: 1523–1529.

  • 105

    Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ 2011; 343: d3450.

  • 106

    Cheema AA. Should people on aspirin avoid ibuprofen? A review of the literature. Cardiol Rev. 2004; 12: 174–176.

  • 107

    Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001; 345: 1809–1817.

  • 108

    Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108: 1191–1195.

  • 109

    Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci USA 2001; 98: 14583–14588.

  • 110

    Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther. 2006; 80: 264–274.

  • 111

    Wilcox CM, Allison J, Benzuly K, et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol. 2006; 4: 1082–1089.

  • 112

    Ofman JJ, MacLean CH, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol. 2002; 29: 804–812.

  • 113

    Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 2005; 100: 1685–1693.

  • 114

    Wheatley KE, Snyman JH, Brearley S, et al. Mortality in patients with bleeding peptic ulcer when those aged 60 or over are operated on early. BMJ 1990; 301: 272.

  • 115

    Rockall TA. Management and outcome of patients undergoing surgery after acute upper gastrointestinal haemorrhage. Steering Group for the National Audit of Acute Upper Gastrointestinal Haemorrhage. J R Soc Med. 1998; 91: 518–523.

  • 116

    Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012; 35: 1127–1146.

  • 117

    Knijff-Dutmer EA, Schut GA, van de Laar MA. Concomitant coumarin-NSAID therapy and risk for bleeding. Ann Pharmacother. 2003; 37: 12–16.

  • 118

    Davidson BL, Verheijen S, Lensing AW, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med. 2014; 174: 947–953.

  • 119

    Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014; 63: 2141–2147.

  • 120

    Lanas A, Garcia-Rodriguez LA, Polo-Tomás M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009; 104: 1633–1641.

  • 121

    Fujimori S, Gudis K, Takahashi Y, et al. Distribution of small intestinal mucosal injuries as a result of NSAID administration. Eur J Clin Invest. 2010; 40: 504–510.

  • 122

    Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010; 8: 504–508.

  • 123

    Laine L, Smith R, Min K, et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2006; 24: 751–767.

  • 124

    Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005; 3: 133–141.

  • 125

    Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol. 2009; 5: 677–684.

  • 126

    Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015; 74: 480–489.

  • 127

    Tsai WC, Ou TT, Yen JH, et al. Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One 2015; 10: e0126347.

  • 128

    Lanas A, Tornero J, Zamorano J. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis. 2010; 69: 1453–1458.

  • 129

    Abdel Shaheed C, Maher CG, Williams KA, et al. Interventions available over the counter and advice for acute low back pain: systematic review and meta-analysis. J Pain 2014; 15: 2–15.

  • 130

    Osteoarthritis: Care and management in adults. NICE clinical guideline [CG177]. Issued: February 2014. http://guidance.nice.org.uk/cg177

  • 131

    Sinusas K. Osteoarthritis: diagnosis and treatment. Am Fam Physician 2012; 85: 49–56.

  • 132

    Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician 2013; 87: 766–772.

  • 133

    Qaseem A, Wilt TJ, McLean RM, et al., for the Clinical Guidelines Committee of the American College of Physicians. Noninvasive treatments for acute, subacute, and chronic low back pain: A Clinical Practice Guideline from the American College of Physicians. Ann Intern Med. 2017; 166: 514–530.

  • 134

    Chou R, Deyo R, Friedly J, et al. Systemic pharmacologic therapies for low back pain: A systematic review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017; 166: 480–492.

  • 135

    Bruyére O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis – From evidence-based medicine to real-life setting. Semin Arthritis Rheum. 2016; 45(4 Suppl): S3–S11.

  • 136

    Derry S, Moore RA, Gaskell H, et al. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015; 6: CD007402.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2021 0 8 179
Feb 2021 0 11 170
Mar 2021 0 14 195
Apr 2021 0 8 175
May 2021 0 4 118
Jun 2021 0 4 56
Jul 2021 0 0 0